AstraZeneca Raises FY 2026 Revenue Guidance Amid Strong Q4 Results

AstraZeneca's stock rose by 3.31% as it reached a 52-week high, reflecting positive investor sentiment following its strong Q4 earnings report.

The company reported a Q4 Non-GAAP EPS of $2.12 and revenue of $15.5 billion, exceeding market expectations by $60 million and indicating robust performance in the biopharmaceutical sector. AstraZeneca also raised its FY 2026 revenue guidance, projecting mid-to-high single-digit growth, which has further boosted investor confidence despite a setback with the FDA denying approval for a subcutaneous version of its lupus drug.

This strong financial performance and optimistic future guidance suggest that AstraZeneca is well-positioned for continued growth, although the FDA setback may pose challenges. Investors will be closely monitoring the company's ability to navigate these challenges while capitalizing on its growth opportunities.